G1 Therapeutics Receivables

G1 Therapeutics (GTHX) currently reports a receivables of $13M as of June 2024. That compares with $13M in the prior-year period — up 1.0% year over year. Use the charts on this page to explore G1 Therapeutics's receivables history and peer comparisons.

G1 Therapeutics's receivables increased from $13M to $13M — a 1.0% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

G1 Therapeutics reported $13M in receivables as of June 2024. That compares with $13M in the prior-year period — up 1.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for G1 Therapeutics, and consider following GTHX for alerts when major investors trade the stock.

G1 Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $13M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GTHX with unrelated industries.